Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H20N2O3 |
Molecular Weight | 264.3207 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CCCC(=NO)O)CCC(=Nc1ccccc1)O
InChI
InChIKey=WAEXFXRVDQXREF-UHFFFAOYSA-N
InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
Molecular Formula | C14H20N2O3 |
Molecular Weight | 264.3207 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB02546Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB02546
Curator's Comment:: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat inhibits the enzymatic activity of histone deacetylases HDAC1, HDAC2 and HDAC3 (Class I) and HDAC6 (Class II) at nanomolar concentrations (IC50< 86 nM). These enzymes catalyze the removal of acetyl groups from the lysine residues of histones proteins. In some cancer cells, there is an overexpression of HDACs, or an aberrant recruitment of HDACs to oncogenic transcription factors causing hypoacetylation of core nucleosomal histones. By inhibiting histone deacetylase, vorinostat causes the accumulation of acetylated histones and induces cell cycle arrest and/or apoptosis of some transformed cells. The mechanism of the antineoplastic effect of vorinostat has not been fully characterized. Vorinostat is used for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is marketed under the name Zolinza by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22090453
Curator's Comment:: Vorinostat was shown to cross the blood-brain barrier in a mouse model of Huntington's disease. It inhibited the growth of GL26 GBM cells implanted into the brains of mice. Vorinostat treatment induced accumulation of acetylated histones H2B, H3, and H4 in patients with recurrent GBM.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2366922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26199860 |
0.12 µM [IC50] | ||
Target ID: CHEMBL1075544 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.13 µM [IC50] | ||
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.15 µM [IC50] | ||
Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
0.28 µM [IC50] | ||
Target ID: CHEMBL3192 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25953722 |
1.68 µM [IC50] | ||
Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19410459 |
57.0 nM [IC50] | ||
Target ID: CHEMBL1865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25734520 |
1.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Zolinza Approved UseTreatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Launch Date1.16000634E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 μM |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
0.83 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
1.17 uM Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.5 μM × h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
4.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
5.59 uM*h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
|
1.94 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg single, oral dose: 400 mg route of administration: oral experiment type: single co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
|
2.3 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00771472 |
400 mg 1 times / day steady, oral dose: 400 mg route of administration: oral experiment type: steady co-administered: |
VORINOSTAT plasma | Homo sapiens population: unhealthy age: sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
VORINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 2 times / day multiple, oral Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 63 years (range: 38 - 74 years) n = 5 Health Status: unhealthy Condition: advanced multiple myeloma Age Group: 63 years (range: 38 - 74 years) Population Size: 5 Sources: |
DLT: Fatigue... Dose limiting toxicities: Fatigue (grade 3, 1 patient) Sources: |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Disc. AE: Thrombocytopenia, Anemia... Other AEs: Hypotension, Sepsis... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 3-4, 8%) Other AEs:Anemia (grade 3-4, 17%) Deep vein thrombosis (grade 3-4, 25%) Pyrexia (grade 3-4, 25%) Pulmonary embolism (grade 3-4, 17%) Hypotension (grade 3-4, 17%) Sources: Sepsis (grade 3-4, 8%) Fatigue (all grades, 27%) Diarrhea (11%) Nausea (8%) Dysgeusia (11%) Weight loss (3%) Vomiting (11%) Anorexia (3%) Blood creatinine increased (8%) Dehydration (5%) Anemia (5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Fatigue | grade 3, 1 patient DLT, Disc. AE |
250 mg 2 times / day multiple, oral Dose: 250 mg, 2 times / day Route: oral Route: multiple Dose: 250 mg, 2 times / day Sources: |
unhealthy, 63 years (range: 38 - 74 years) n = 5 Health Status: unhealthy Condition: advanced multiple myeloma Age Group: 63 years (range: 38 - 74 years) Population Size: 5 Sources: |
Diarrhea | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Dysgeusia | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Vomiting | 11% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anorexia | 3% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Weight loss | 3% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anemia | 5% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Dehydration | 5% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Blood creatinine increased | 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Nausea | 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Fatigue | all grades, 27% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Hypotension | grade 3-4, 17% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Anemia | grade 3-4, 17% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Pulmonary embolism | grade 3-4, 17% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Deep vein thrombosis | grade 3-4, 25% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Pyrexia | grade 3-4, 25% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Sepsis | grade 3-4, 8% | 300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Thrombocytopenia | grade 3-4, 8% Disc. AE |
300 mg 2 times / day multiple, oral (starting) Highest studied dose Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: |
unhealthy, 69 years (range: 26.0 - 80.0 years) n = 12 Health Status: unhealthy Condition: cutaneous Tcell lymphoma Age Group: 69 years (range: 26.0 - 80.0 years) Sex: M+F Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 31.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. | 2001 |
|
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. | 2001 Dec 1 |
|
Phosphorus-based SAHA analogues as histone deacetylase inhibitors. | 2003 Aug 21 |
|
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. | 2003 Dec |
|
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. | 2003 Mar 1 |
|
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. | 2003 May 1 |
|
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. | 2003 May 1 |
|
Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. | 2004 Dec |
|
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. | 2004 Feb 9 |
|
Gateways to clinical trials. | 2004 Jun |
|
[Therapeutic targets in polyglutamine diseases]. | 2004 May |
|
The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). | 2004 May |
|
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. | 2004 May 15 |
|
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. | 2004 Nov |
|
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol. | 2004 Oct |
|
High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. | 2005 |
|
Histone deacetylase inhibitors in programmed cell death and cancer therapy. | 2005 Apr |
|
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. | 2005 Aug |
|
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. | 2005 Aug |
|
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. | 2005 Aug 1 |
|
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. | 2005 Dec |
|
Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. | 2005 Jan 17 |
|
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. | 2005 Jul |
|
Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. | 2005 Jul |
|
Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. | 2005 Jul 1 |
|
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. | 2005 Jul 28 |
|
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. | 2005 Jun |
|
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. | 2005 Jun 10 |
|
4-Hydroxybenzoyl derivative from the aqueous extract of the hydroid Campanularia sp. | 2005 Mar |
|
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. | 2005 Mar |
|
[Histone deacetylase inhibitors as a new generation of anti-cancer agents]. | 2005 Mar 11 |
|
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. | 2005 Mar 15 |
|
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. | 2005 May |
|
Novel histone deacetylase inhibitors in the treatment of thyroid cancer. | 2005 May 15 |
|
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. | 2005 Nov |
|
Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus. | 2005 Nov 1 |
|
Crystal structure of a bacterial class 2 histone deacetylase homologue. | 2005 Nov 18 |
|
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. | 2005 Sep |
|
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. | 2005 Sep |
|
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | 2005 Sep 1 |
|
Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. | 2005 Sep 1 |
|
Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. | 2005 Sep 23 |
|
Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. | 2006 Apr 6 |
|
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. | 2006 Jan |
|
SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. | 2006 Jan |
|
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. | 2006 Jan 1 |
|
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis. | 2006 Jul 1 |
|
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. | 2006 Mar |
|
Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. | 2006 Mar 3 |
|
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. | 2006 May 15 |
Patents
Sample Use Guides
400 mg orally once daily with food.
If patient is intolerant to therapy, the dose may be reduced to
300 mg orally once daily with food. If necessary, the dose may be
further reduced to 300 mg once daily with food for 5 consecutive
days each week.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23856614
Concentrations of vorinostat higher than 0.5 uM significantly inhibited the upregulated gene expression of MMP-1 and MMP-13 induced by IL-1β, whereas 0.1 uM vorinostat showed no obvious effect. Conversely, 0.5 uM vorinostat or higher concentration increased the TIMP-1 expression.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 22:11:30 UTC 2021
by
admin
on
Fri Jun 25 22:11:30 UTC 2021
|
Record UNII |
58IFB293JI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
177203
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
WHO-VATC |
QL01XX38
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/11/854
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
LIVERTOX |
1040
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
NCI_THESAURUS |
C1946
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
NDF-RT |
N0000175588
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
FDA ORPHAN DRUG |
540116
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
WHO-ATC |
L01XX38
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
NDF-RT |
N0000175071
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
FDA ORPHAN DRUG |
174203
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
||
|
FDA ORPHAN DRUG |
169503
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL98
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
4124
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
149647-78-9
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
M11502
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | Merck Index | ||
|
7930
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
5311
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
194337
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | RxNorm | ||
|
58IFB293JI
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
C111237
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
8661
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
C1796
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
6852
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
VORINOSTAT
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
149647-78-9
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
SUB23356
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY | |||
|
DB02546
Created by
admin on Fri Jun 25 22:11:31 UTC 2021 , Edited by admin on Fri Jun 25 22:11:31 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET ORGANISM->INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
BINDING
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
blood-to-plasma ratio | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
FED CONDITION |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
INTRAVENOUS ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||